Corticosteroid Sclerotherapy of Morel-Lavallée Syndrome: about a Case at the Reference Health Center (CSRéf) Commune III of Bamako

Abstract

Morel-Lavallée syndrome corresponds to a serolymphatic effusion secondary to tangential trauma in relation to a richly vascularized tissue. It is a pathology little mentioned in the medical literature. We report the case of a female patient, victim of a road traffic accident which caused a Morel-lavallée lesion and who was successfully treated by sclerotherapy with corticosteroid (triamcinolone). There is currently no universally accepted treatment algorithm for the management of Morel-Lavallée lesions. Corticosteroids constitute a valid therapeutic option as a sclerosing agent in the treatment of this pathology. Conclusion: Corticosteroids constitute a valid therapeutic option as a sclerosing agent in the treatment of Morel-lavallée syndrome with satisfactory results.